. 2019 Mar 20;5(3):eaav3801. doi: 10.1126/sciadv.aav3801

Table 1. Participant demographics and clinical details.

Twenty-five patients per group completed the study. One patient in group B was not included in analyses because of outlier-level performance on the DSST before recognition testing. Groups A and B did not differ on any demographical variables (age, gender, years of education, or type of endoscopy procedure) or in terms of dosage of other agents (midazolam or alfentanil) administered. However, there was a significant difference in the amount of propofol administered.

		Group A	Group B	Statistic (t, X²)	P
Gender*	Female	10	9	$χ_{(1)}^{2} = 0.32$	0.86
Gender*	Male	15	15	$χ_{(1)}^{2} = 0.32$	0.86
Age (years)^†	Mean	38.88	39.08	t₄₇ = −0.15	0.88
Age (years)^†	SEM	0.90	0.97	t₄₇ = −0.15	0.88
Years of schooling^†	Mean	14.44	14.75	t₄₇ = −0.38	0.70
Years of schooling^†	SEM	0.60	0.54	t₄₇ = −0.38	0.70
Endoscopy procedure*	Colonoscopy	13	10	$χ_{(2)}^{2} = 2.97$	0.23
	Gastroscopy	7	12
	Both	5	2
Endoscopy diagnosis*	Not pathological	15	18	$χ_{(5)}^{2} = 2.6$	0.76
	Inflammatory	4	3
	Allergy	1	1
	Vascular	1	0
	Ulcer	1	0
	Polyps	3	2
Propofol (mg/kg)^†	Mean	3.02	2.37	t₄₇ = 2.04	0.047^‡
Propofol (mg/kg)^†	SEM	0.25	0.19	t₄₇ = 2.04	0.047^‡
Duration of deep sedation (min)^†	Mean	13.17	11.42	t₄₇ = 0.93	0.36
Duration of deep sedation (min)^†	SEM	1.56	1.02	t₄₇ = 0.93	0.36
Other pharmacological agents*	Yes	13	13	$χ_{(1)}^{2} = 0.023$	0.88
Other pharmacological agents*	No	12	11	$χ_{(1)}^{2} = 0.023$	0.88
Midazolam in mg^†	n	8	8
	Mean	2.05	1.37	t₁₄ = 1.65	0.12
	SEM	0.35	0.21	t₁₄ = 1.65	0.12
Alfentanil in mg^†	n	7	7
	Mean	0.29	0.30	t₁₂ = −0.08	0.94
	SEM	0.06	0.06	t₁₂ = −0.08	0.94

*χ².

†Independent t test.

‡Significant at P < 0.05.